MX2018008447A - Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal. - Google Patents

Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.

Info

Publication number
MX2018008447A
MX2018008447A MX2018008447A MX2018008447A MX2018008447A MX 2018008447 A MX2018008447 A MX 2018008447A MX 2018008447 A MX2018008447 A MX 2018008447A MX 2018008447 A MX2018008447 A MX 2018008447A MX 2018008447 A MX2018008447 A MX 2018008447A
Authority
MX
Mexico
Prior art keywords
species
level
monoclonal antibodies
culture
modulation
Prior art date
Application number
MX2018008447A
Other languages
English (en)
Spanish (es)
Inventor
Santoro Marc
John Jose Kevin
Madabhushi Sri
Gangloff Scott
Original Assignee
Oncobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018008447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncobiologics Inc filed Critical Oncobiologics Inc
Publication of MX2018008447A publication Critical patent/MX2018008447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2018008447A 2016-01-06 2017-01-05 Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal. MX2018008447A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (1)

Publication Number Publication Date
MX2018008447A true MX2018008447A (es) 2019-05-30

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008447A MX2018008447A (es) 2016-01-06 2017-01-05 Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.

Country Status (8)

Country Link
US (1) US20190161543A1 (enExample)
EP (1) EP3400241B1 (enExample)
JP (1) JP6674028B2 (enExample)
CN (1) CN109153716A (enExample)
AU (1) AU2017206006B2 (enExample)
CA (1) CA3010598A1 (enExample)
MX (1) MX2018008447A (enExample)
WO (1) WO2017120347A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US12325737B2 (en) * 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CA3123591A1 (en) * 2018-12-19 2020-06-25 Seagen Inc. Controlled fucosylation of antibodies
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies
US20240141020A1 (en) * 2021-02-12 2024-05-02 Lonza Bend Inc. Method for modulating afucoslyation of an antibody product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
ATE515566T1 (de) 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PL2282773T3 (pl) * 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
DK2808393T3 (en) 2009-06-02 2018-03-12 Regeneron Pharma Cells insufficient for fucosylation
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (enExample) * 2012-10-01 2018-08-04
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
CN108431026B (zh) * 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Also Published As

Publication number Publication date
JP2019500876A (ja) 2019-01-17
EP3400241B1 (en) 2020-07-22
US20190161543A1 (en) 2019-05-30
CA3010598A1 (en) 2017-07-13
CN109153716A (zh) 2019-01-04
JP6674028B2 (ja) 2020-04-01
EP3400241A1 (en) 2018-11-14
WO2017120347A1 (en) 2017-07-13
AU2017206006A1 (en) 2018-07-19
AU2017206006B2 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2018008448A (es) Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
Li et al. The multifaceted regulation and functions of PKM2 in tumor progression
GEP20237513B (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
SG10201903912XA (en) Delivery of biomolecules to immune cells
MX2020004094A (es) Metodos para administrar inmunoterapia con receptores de antigeno quimerico.
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
MY200337A (en) Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
GB2555728A (en) Cancer cell enrichment system
EP4303229A3 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HK1243631A1 (zh) 用於提高过继细胞免疫疗法效力的组合物和方法
MX2021001859A (es) Medio de cultivo celular libre de suero.
EP4279136A3 (en) Methods for determining car-t cells dosing
MX2020013695A (es) Biorreactores de peque?o volumen con volumenes de trabajo sustancialmente constantes y sistemas y metodos relacionados.
IL269197A (en) Control of fully apocosylated antibody glycoforms produced in cell culture
IL276910A (en) Fully fucose-free glycoforms of antibodies are produced in cell culture
MX366106B (es) Composiciones y metodos para producir glucoproteinas.
AU2016335217A8 (en) Antigen receptors and uses thereof
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX2015010428A (es) Anticuerpos anti-her2 altamente galactosilados y sus usos.
IN2014MU01100A (enExample)
AU2017254665A1 (en) Compositions and methods for enhanced gene expression of pklr
MX2015017414A (es) Bacteria acetogenica.
WO2020012244A3 (en) Treating ulcerative colitis with brazikumab